Portugal’s Medicines Agency Clarifies When Health Apps and AI Qualify as Medical Devices

The integration of digital health medical devices into modern healthcare systems requires careful regulatory oversight to ensure patient safety and data reliability. According to INFARMED guidance, these solutions only qualify as medical devices when manufacturers explicitly intend them for prevention, diagnosis, monitoring, treatment, or clinical decision support, backed by robust clinical and scientific evidence. This distinction is critical because it determines whether solutions must adhere to strict European standards rather than operating in a less regulated wellness space.

Qualification of Digital Health Medical Devices

Qualification follows a purpose-driven assessment that compares the manufacturer’s stated intended use against the legal definition of a medical device. Risk classification then guides the conformity pathway, with classes IIa, IIb, and III requiring notified body involvement while lower-risk items may rely on self-assessment. Post-market surveillance obligations further ensure ongoing safety monitoring after market entry.

Compliance Pathways Under MDR and IVDR

Solutions qualify as digital health medical devices only when they meet the criteria set by the Medical Device Regulation (MDR), Regulation (EU) 2017/745, the In Vitro Diagnostic Regulation (IVDR), Regulation (EU) 2017/746, and Portuguese national rules such as Decreto-Lei nº 29/2024. Valid CE marking, supported by notified body assessment where required, serves as the primary indicator of compliance. Administrative tools for billing or scheduling, along with general wellness trackers, remain outside this scope because they lack a documented medical purpose. In contrast, applications that analyze clinical parameters or support diagnostic interpretation must demonstrate conformity through a declaration of conformity and, where applicable, notified body certification.

Ad

Strategic Implications for Healthcare Stakeholders

Health technology assessment bodies and payers should embed regulatory status verification into procurement protocols to prevent reliance on unassessed tools. Manufacturers pursuing reimbursement or institutional adoption must supply detailed evidence of both intended purpose and conformity at the acquisition stage. This framework influences pricing negotiations and coverage decisions by limiting eligibility to technologies whose performance claims rest on completed conformity procedures. For authoritative details on entity requirements, consult the official INFARMED resource on medical devices. The emphasis on verified data ultimately strengthens trust in digital solutions integrated into clinical pathways, supporting safer and more effective care delivery across Europe.